Clarithromycin-based triple therapy의 H. pylori 제균율은 clarithromycin 저항성이 높은 지역에서는 낮습니다. Clarithromycin-based triple therapy에 bismuth를 추가하였을 때(14일 치료) H. pylori 제균율은 90 % 이상이었습니다.
What's New
Eradication of H. pylori by adding bismuth to clarithromycin-based triple therapy (January 2020)
Eradication rates for H. pylori with clarithromycin-based triple therapy are low in areas of high clarithromycin resistance. In a study of over 1000 treatment-naïve patients with H. pylori, the addition of bismuth to clarithromycin-based triple therapy for 14 days resulted in eradication of H. pylori in over 90 percent of patients, with an acceptable safety profile and adherence. Until further studies validate these results, for patients with risk factors for macrolide resistance, we use bismuth quadruple therapy, which does not include clarithromycin.
REF. Clin Gastroenterol Hepatol. 2020;18(1):89. Epub 2019 Apr 10.
UpToDate 2020.03.26
